Phase 2 Placebo-Controlled Trial of Two Vaccines to Prevent Ebola in Liberia | Zendy

Stephen B. Kennedy | Zendy; Fatorma K. Bolay | Zendy; Mark Kieh | Zendy; Greg Grandits | Zendy; Moses Badio | Zendy; Ripley W. Ballou | Zendy; Risa Eckes | Zendy; Mark B. Feinberg | Zendy; Dean Follmann | Zendy; Birgit Grund | Zendy; Swati Gupta | Zendy; Lisa E. Hensley | Zendy; Elizabeth S. Higgs | Zendy; Krisztina Janosko | Zendy; Melvin Johnson | Zendy; Francis Kateh | Zendy; James Logue | Zendy; Jonathan Marchand | Zendy; Thomas P. Monath | Zendy; Martha Nason | Zendy; Tolbert Nyenswah | Zendy; François Roman | Zendy; Eric Stavale | Zendy; Julian Wolfson | Zendy; James D. Neaton | Zendy; H. Clifford Lane | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Phase 2 Placebo-Controlled Trial of Two Vaccines to Prevent Ebola in Liberia

Author(s) -

Stephen B. Kennedy,

Fatorma K. Bolay,

Mark Kieh,

Greg Grandits,

Moses Badio,

Ripley W. Ballou,

Risa Eckes,

Mark B. Feinberg,

Dean Follmann,

Birgit Grund,

Swati Gupta,

Lisa E. Hensley,

Elizabeth S. Higgs,

Krisztina Janosko,

Melvin Johnson,

Francis Kateh,

James Logue,

Jonathan Marchand,

Thomas P. Monath,

Martha Nason,

Tolbert Nyenswah,

François Roman,

Eric Stavale,

Julian Wolfson,

James D. Neaton,

H. Clifford Lane

Publication year - 2017

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1614067

Subject(s) - medicine , placebo , ebola vaccine , adverse effect , ebola virus , immunogenicity , incidence (geometry) , randomization , clinical trial , virology , immunology , disease , immune system , pathology , physics , alternative medicine , optics

The safety and efficacy of vaccines to prevent Ebola virus disease (EVD) were unknown when the incidence of EVD was peaking in Liberia.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research